Clik here to view.
Genmab makes two C-suite additions as COO leaves; James Sabry leads a...
Anthony Mancini → There are substantial leadership changes at Genmab, starting with the departure of COO Anthony Mancini. Peer Review covered Mancini’s appointment in March 2020 following a 24-year...
View ArticleClik here to view.
Jazz will still file anti-seizure med Epidiolex in Japan despite trial setback
Jazz Pharmaceuticals’ oral cannabidiol drug Epidiolex has disappointed in a late-phase test in Japanese children with seizures, but the company will still file there based on its global dataset....
View ArticleNovo's innovation hub expands to Bay Area; SIGA's new Tpoxx order
Novo Nordisk’s Bio Innovation Hub goes west: The Danish pharma’s early-stage R&D unit is partnering with MBC BioLabs, an incubator in the San Francisco Bay Area that has helped launch more than 300...
View ArticleCDER chief says 'standards have not changed,' explaining increase in CRLs for...
The FDA initially rejected nearly half of all biologics applications received last year, many for quality-related CMC issues that need to be improved upon, according to CDER Director Patrizia...
View ArticleJ&J grants 'short extension' for certification of talc settlement vote
Talc claimants will have to wait a bit longer for the results of a vote on J&J’s proposed $6.5 billion settlement plan. The company on Friday announced a “short extension” of its process to certify...
View ArticleResearchers downplay study that found a link between semaglutide and mental...
A growing body of research has done little to clear up concerns about whether there’s a link between GLP-1 drugs and depression, suicidal ideation and self harm. The latest research, an observational...
View ArticleTome Biosciences to lay off almost all workers
Tome Biosciences, a high-profile gene editing startup, will terminate nearly its entire workforce during the first two weeks of November. It disclosed plans to lay off 131 people in a Massachusetts...
View ArticleTome plans layoffs amid struggle; FDA turns away Regeneron; Next-gen obesity...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View ArticleClik here to view.
Major Galapagos investor says it will push board on company's 'performance'...
One of Galapagos’ biggest shareholders is taking a more active role in pushing the company’s turnaround. Biotech investment firm EcoR1 Capital, which owns 9.9% of the company’s shares, said in a Friday...
View ArticleMpox vaccine collab; $11M oncology seed; Gates backs RSV vaccine; Kyowa Kirin...
Houston biotech closes $11.4 million seed round: Diakonos Oncology said the money will fund operations into late 2025. A Phase 2 trial testing its dendritic cell vaccine program in glioblastoma is...
View ArticleClik here to view.
Once one of immuno-oncology's next great hopes, CD47 faces final shots on goal
Earlier this summer, a small biotech company’s readout in what was once one of cancer’s most intriguing approaches did little to settle the controversy and questions surrounding it. The CD47 pathway,...
View ArticleRegeneron wins EU approval for lymphoma bispecific following FDA rejection
EU regulatory authorities granted conditional approval to Regeneron’s bispecific antibody odronextamab for two forms of lymphoma. It’s Regeneron’s first bispecific antibody approval in the world after...
View ArticleAnother major PBM will cut AbbVie's Humira from its largest commercial...
Cigna’s pharmacy benefit manager Express Scripts said it will remove Humira from its largest commercial drug formularies in 2025 to make way for its biosimilars. The move will make Express Scripts the...
View ArticleNovartis to sell molecular imaging business to Siemens Healthineers
Novartis is selling off its molecular imaging business for positron emission tomography (PET) scans to Siemens Healthineers for an undisclosed amount, both companies confirmed to Endpoints News on...
View ArticleFederal agency opposes J&J's new 340B discount model, promises to take...
The federal government is challenging Johnson & Johnson’s plan to change how some hospitals receive drug price discounts under the 340B program. Last week, J&J announced that beginning Oct. 15,...
View ArticleClik here to view.
Swiss biotech's inhibitor of cancer driver shows promise in rare bleeding...
Vaderis Therapeutics announced Tuesday morning that its lead drug candidate, an AKT inhibitor, helped reduce nosebleeds in people with hereditary hemorrhagic telangiectasia, a genetic disorder in which...
View ArticlePfizer unveils direct-to-consumer push for Covid, flu and migraine treatments
Pfizer is expanding its direct-to-patient sales offerings. On Tuesday, the New York pharma launched a new website, called PfizerForAll, that connects patients to clinicians who can prescribe its...
View ArticleUpdated: Oculis closes Phase 3 eye drop trial due to 'administrative error'...
A Phase 3 trial for Oculis’ lead eye drop candidate will be shut down due to an administrative error, the company reported in its second-quarter financial filing. The OPTIMIZE-2 trial was investigating...
View ArticleRA Capital and Forbion set up new autoimmune biotech with bispecific from...
Another autoimmune biotech emerged on Tuesday morning with a $100 million Series A. Navigator Medicines launched with a license to a Phase 1 bispecific antibody and a pipeline of other assets from...
View ArticleClik here to view.
Elektrofi, a startup that helps drugmakers formulate biologics for easier...
Biologics startup Elektrofi is raising an approximately $112 million Series C, CEO and co-founder Chase Coffman confirmed to Endpoints News. Chase Coffman The Boston-based startup works with pharma and...
View Article